

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597022
Filing Date	2007-06-18
First Named Inventor	Chen et al.
Art Unit	1625
Examiner Name	Taylor V. Oh
Attorney Docket Number	22727/04418

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5776888		1988-07-07	Leone-Bay	

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030225054		2003-12-04	Duan	
	2	20090137679		2009-05-28	Chen	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	01/16106	WO		2001-03-08	Schering AG		<input type="checkbox"/>
	2	01/34131	WO		2001-05-17	Warner		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597022
Filing Date	2007-06-18
First Named Inventor	Chen et al.
Art Unit	1625
Examiner Name	Taylor V. Oh
Attorney Docket Number	22727/04418

3	02/26696	WO		2002-04-04	Prolifix Ltd.		<input type="checkbox"/>
4	02/74298	WO		2002-09-26	Ono Pharmaceutical		<input type="checkbox"/>
5	03/13493	WO		2003-02-20	Italfarmaco SPA		<input type="checkbox"/>
6	05/055928	WO		2005-06-23	The Ohio State University Research Foundation		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Office action from U.S. Serial No. 12/361,626 dated 09/23/2009.	<input type="checkbox"/>
	2	Amendment from U.S. Serial No. 12/361,626 dated 01/25/2010.	<input type="checkbox"/>
	3	Supplemental Amendment from U.S. Serial No. 12/361,626 dated 02/24/2010.	<input type="checkbox"/>
	4	Office action from U.S. Serial No. 12/361,626 dated 05/28/2010.	<input type="checkbox"/>
	5	European Search report dated June 1, 2010 from EP Application No. 04812666.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597022
Filing Date	2007-06-18
First Named Inventor	Chen et al.
Art Unit	1625
Examiner Name	Taylor V. Oh
Attorney Docket Number	22727/04418

6	FINNIN et al., "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors", <i>Nature</i> , 401, 188-193, 1999	<input type="checkbox"/>
7	FUINO, et al, "Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B", <i>Mol Cancer Ther</i> , 2, 971-984, 2003	<input type="checkbox"/>
8	FURUMAI et al., "Potent histone deacetylase inhibitors build from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin", <i>Proc Natl Acad Sci USA</i> , 98: 87-92, 2001	<input type="checkbox"/>
9	GROZINGER et al. "Deacetylase enzymes: biological functions and the use of small-molecule inhibitors", <i>Chem Biol</i> 9: 3-16, 2002	<input type="checkbox"/>
10	JOHNSTONE, "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer", <i>Nat Rev Drug Discov</i> , 1: 287-299, 2002	<input type="checkbox"/>
11	KIJIMA et al., "Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase", <i>J Biol Chem</i> , 268, 22429-22435, 1993	<input type="checkbox"/>
12	KRAMER et al. "Histone deacetylase as a therapeutic target", <i>Trends Endocrinol Metab</i> , 12: 294-300, 2001	<input type="checkbox"/>
13	LEA et al., "Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase", <i>Anticancer Res</i> , 15, 879-883, 1995	<input type="checkbox"/>
14	LU, et al., "Zn ²⁺ -chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors", <i>J Med Chem</i> , 47, 467-474, 2004	<input type="checkbox"/>
15	MARKS et al. "Histone deacetylases and cancer: causes and therapies", <i>Nat. Rev. Cancer</i> 1: 194-202, 2001	<input type="checkbox"/>
16	NAKAJIMA et al., "FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor", <i>Exp Cell Res</i> 241, 126-133, 1998	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597022
Filing Date	2007-06-18
First Named Inventor	Chen et al.
Art Unit	1625
Examiner Name	Taylor V. Oh
Attorney Docket Number	22727/04418

17	REMISZEWSKI et al., "Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates" J Med Chem, 45, 753-757, 2002	<input type="checkbox"/>
18	RICHON et al., "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases", Proc Natl Acad Sci USA 95 3003-3007, 1998	<input type="checkbox"/>
19	SHUTE et al., "Analogues of the cytostatic and antimitogenic agents chlamydocin and HC-toxin: synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptides", J Med Chem 30, 71-78, 1987	<input type="checkbox"/>
20	STERNSON et al., "Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin", Org. Lett. 3, pp. 4239-4242 (2001)	<input type="checkbox"/>
21	VANOMMESLAEGHE et al., "Ab initio study of the binding of Trichostatin A (TSA) in the active site of histone deacetylase like protein (HdLP)", Org Biomol Chem, 1, 2951-2957, 2003	<input type="checkbox"/>
22	HAN et al., "Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin", Cancer Res, 60, 6068-6074, 2000	<input type="checkbox"/>
23	JUNG et al., "Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation", J Med Chem 42, 4669-4679, 1999	<input type="checkbox"/>
24	KIM et al., "Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA", Cancer Res 63, 7291-7300, 2003	<input type="checkbox"/>
25	KIM et al., "Synthesis and Biological Evolution of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors", J of Medicinal Chemistry, American Chemical Society, vol. 46, no. 26, January 1, 2003, pp. 5745-5751	<input type="checkbox"/>
26	KRAKER et al., "Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma", Mol Cancer Ther, 2, 401-408, 2003	<input type="checkbox"/>
27	LU et al., "Efficacy of a Novel Histone Deacetylase Inhibitor in Murine Models of Hepatocellular Carcinoma", Hepatology, pp. 1119-1130, October 2007	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597022
Filing Date	2007-06-18
First Named Inventor	Chen et al.
Art Unit	1625
Examiner Name	Taylor V. Oh
Attorney Docket Number	22727/04418

28	LUCAS et al., "The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells", Leukemia, 18, 1207-1214, 2004	<input type="checkbox"/>
29	MAEDA et al., "Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities", Bioorganic & Medicinal Chemistry, vol. 12, no. 16, pp. 4351-4360, July 1, 2004	<input type="checkbox"/>
30	MARKS et al. "Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells", J Natl Cancer Inst, 92: 1210-1216, 2000	<input type="checkbox"/>
31	MILLER, et al., "Histone deacetylase inhibitors", J Med Chem 46, 5097-5116, 2003	<input type="checkbox"/>
32	PIEKARZ, et al., "T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance", Blood, 103, 4636-4643, 2004	<input type="checkbox"/>
33	YANG et al., "A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer", Neoplasia, vol. 11, no. 6, June 2009, pp. 552-563	<input type="checkbox"/>
34	LUCAS et al., "The novel deacetylase inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo", PLOS ONE, vol. 5, issue 6, pp 1-10, June 2010	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.